XML 73 R57.htm IDEA: XBRL DOCUMENT
v3.21.2

Common Stock, Preferred Stock and Warrants - Additional Information (Detail) - USD ($) |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | ---
Aug. 06, 2020 | Nov. 03, 2017 | May 31, 2020 | Aug. 31, 2019 | Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 | Aug. 12, 2019
Class Of Stock [Line Items] |  |  |  |  |  |  |  |  |  |
Common stock, shares outstanding |  |  |  |  | 114,756,092 |  | 114,756,092 |  | 110,190,000 |
Issuance of common stock and preferred stock (in shares) |  |  |  | 18,525,000 |  |  |  |  |  |
Common stock, par value |  |  |  | $ 0.001 | $ 0.001 |  | $ 0.001 |  | $ 0.001 |
Preferred stock, par value |  |  |  |  | $ 0.001 |  | $ 0.001 |  | $ 0.001 |
Net cash proceeds received |  |  |  |  |  |  | $ 28,156,000 | $ 107,697,000 |  |
Change in fair value of warrant liability |  |  |  |  | $ (2,097,000) | $ 25,655,000 | $ 23,455,000 | $ 17,045,000 |  |
Common Stock |  |  |  |  |  |  |  |  |  |
Class Of Stock [Line Items] |  |  |  |  |  |  |  |  |  |
Issuance of common stock and preferred stock (in shares) |  |  |  |  |  | 21,197,000 | 2,879,000 | 24,106,000 |  |
Warrants |  |  |  |  |  |  |  |  |  |
Class Of Stock [Line Items] |  |  |  |  |  |  |  |  |  |
Warrants Called for purchase |  |  |  |  | 5,091,000 |  | 5,091,000 |  |  |
Fair value of derivative liability |  |  |  |  | $ 29,600,000 |  | $ 29,600,000 |  |  | $ 7,400,000
Warrants | Other Income, Net |  |  |  |  |  |  |  |  |  |
Class Of Stock [Line Items] |  |  |  |  |  |  |  |  |  |
Change in fair value of warrant liability |  |  |  |  | $ 2,100,000 |  | $ 23,500,000 |  |  |
Bain Life Sciences |  |  |  |  |  |  |  |  |  |
Class Of Stock [Line Items] |  |  |  |  |  |  |  |  |  |
Net cash proceeds received from issuance or sale of equity |  |  |  | $ 35,000,000.0 |  |  |  |  |  |
Bain Life Sciences | Common Stock |  |  |  |  |  |  |  |  |  |
Class Of Stock [Line Items] |  |  |  |  |  |  |  |  |  |
Warrants Called for purchase |  |  |  |  | 2,916,250 |  | 2,916,250 |  |  |
Proceeds From Warrants Sale |  |  |  |  | 11.8 |  | 11.8 |  |  |
Bain Capital Life Sciences Fund, L.P |  |  |  |  |  |  |  |  |  |
Class Of Stock [Line Items] |  |  |  |  |  |  |  |  |  |
Issuance of common stock and preferred stock (in shares) |  |  |  | 6,826,266 |  |  |  |  |  |
Number of common stock allowed to purchase |  |  |  | 2,645,566 |  |  |  |  |  |
Net cash proceeds received from issuance or sale of equity |  |  |  | $ 31,700,000 |  |  |  |  |  |
Bain Capital Life Sciences Fund, L.P | Common Stock |  |  |  |  |  |  |  |  |  |
Class Of Stock [Line Items] |  |  |  |  |  |  |  |  |  |
Warrants Called for purchase |  |  |  |  | 2,645,566 |  | 2,645,566 |  |  |
BCIP Life Sciences Associates, L.P |  |  |  |  |  |  |  |  |  |
Class Of Stock [Line Items] |  |  |  |  |  |  |  |  |  |
Issuance of common stock and preferred stock (in shares) |  |  |  | 698,734 |  |  |  |  |  |
Number of common stock allowed to purchase |  |  |  | 270,684 |  |  |  |  |  |
Net cash proceeds received from issuance or sale of equity |  |  |  | $ 3,200,000 |  |  |  |  |  |
BCIP Life Sciences Associates, L.P | Common Stock |  |  |  |  |  |  |  |  |  |
Class Of Stock [Line Items] |  |  |  |  |  |  |  |  |  |
Warrants Called for purchase |  |  |  |  | 270,684 |  | 270,684 |  |  |
Offering |  |  |  |  |  |  |  |  |  |
Class Of Stock [Line Items] |  |  |  |  |  |  |  |  |  |
Issuance of common stock and preferred stock (in shares) |  |  | 2,100,000 |  |  |  |  |  |  |
Common stock, par value |  |  | $ 0.001 |  |  |  |  |  |  |
Number of common stock allowed to purchase |  |  |  | 0.25 |  |  |  |  |  |
Combined price of common stock and warrant |  |  |  | $ 3.00 |  |  |  |  |  |
Net cash proceeds received from issuance or sale of equity |  |  | $ 75,400,000 | $ 65,600,000 |  |  |  |  |  |
Payment of issuance costs |  |  |  | $ 4,500,000 |  |  |  |  |  |
Price of common stock |  |  | $ 5.00 |  |  |  |  |  |  |
Offering | Bain Capital Life Sciences Fund, L.P |  |  |  |  |  |  |  |  |  |
Class Of Stock [Line Items] |  |  |  |  |  |  |  |  |  |
Issuance of common stock and preferred stock (in shares) |  |  | 1,000,000 |  |  |  |  |  |  |
2017 ATM Agreement |  |  |  |  |  |  |  |  |  |
Class Of Stock [Line Items] |  |  |  |  |  |  |  |  |  |
Issuance of common stock and preferred stock (in shares) |  |  |  |  |  |  | 2,878,567 |  |  |
Net cash proceeds received |  |  |  |  |  |  | $ 28,200,000 |  |  |
Remaining proceeds from common stock, under sales agreement |  |  |  |  |  |  | $ 120,500,000 |  |  |
Series B Convertible Preferred Stock |  |  |  |  |  |  |  |  |  |
Class Of Stock [Line Items] |  |  |  |  |  |  |  |  |  |
Issuance of common stock and preferred stock (in shares) |  |  |  | 4,840 |  |  |  |  |  |
Preferred stock, par value |  |  |  | $ 0.001 |  |  |  |  |  |
Preferred stock, shares outstanding |  |  |  |  | 4,140 |  | 4,140 |  | 4,000 |
Preferred stock deemed dividend |  |  |  |  |  |  | $ 3,300,000 |  |  |
Series B Convertible Preferred Stock | Common Stock |  |  |  |  |  |  |  |  |  |
Class Of Stock [Line Items] |  |  |  |  |  |  |  |  |  |
Number of common stock allowed to purchase |  |  |  |  | 1,000 |  | 1,000 |  |  |
Series B Convertible Preferred Stock | Bain Capital Life Sciences Fund, L.P |  |  |  |  |  |  |  |  |  |
Class Of Stock [Line Items] |  |  |  |  |  |  |  |  |  |
Issuance of common stock and preferred stock (in shares) |  |  |  | 3,756 |  |  |  |  |  |
Series B Convertible Preferred Stock | BCIP Life Sciences Associates, L.P |  |  |  |  |  |  |  |  |  |
Class Of Stock [Line Items] |  |  |  |  |  |  |  |  |  |
Issuance of common stock and preferred stock (in shares) |  |  |  | 384 |  |  |  |  |  |
Series B Convertible Preferred Stock | Offering |  |  |  |  |  |  |  |  |  |
Class Of Stock [Line Items] |  |  |  |  |  |  |  |  |  |
Number of common stock allowed to purchase |  |  |  | 250 |  |  |  |  |  |
Combined price of preferred stock and warrant |  |  |  | $ 3,000 |  |  |  |  |  |
Maximum |  |  |  |  |  |  |  |  |  |
Class Of Stock [Line Items] |  |  |  |  |  |  |  |  |  |
Common stock sales agreement aggregate sales proceeds | $ 150,000,000 |  |  |  |  |  |  |  |  |
Maximum | Warrants |  |  |  |  |  |  |  |  |  |
Class Of Stock [Line Items] |  |  |  |  |  |  |  |  |  |
Percentage of common stock held not to exceed for warrant exercises |  |  |  |  |  |  | 19.99% |  |  |
Maximum | Offering |  |  |  |  |  |  |  |  |  |
Class Of Stock [Line Items] |  |  |  |  |  |  |  |  |  |
Issuance of common stock and preferred stock (in shares) |  |  | 16,100,000 |  |  |  |  |  |  |
Warrant issued |  |  |  | 5,841,250 |  |  |  |  |  |
Maximum | 2017 ATM Agreement |  |  |  |  |  |  |  |  |  |
Class Of Stock [Line Items] |  |  |  |  |  |  |  |  |  |
Common stock sales agreement aggregate sales proceeds |  | $ 150,000,000 |  |  |  |  |  |  |  |
Commission on gross sales proceeds of common stock |  | 3.00% |  |  |  |  |  |  |  |
Maximum | Series B Convertible Preferred Stock |  |  |  |  |  |  |  |  |  |
Class Of Stock [Line Items] |  |  |  |  |  |  |  |  |  |
Percentage of common stock held not to exceed for warrant exercises |  |  |  |  |  |  | 19.99% |  |  |
Minimum | Warrants |  |  |  |  |  |  |  |  |  |
Class Of Stock [Line Items] |  |  |  |  |  |  |  |  |  |
Percentage of common stock to be held for exercise of warrants |  |  |  |  |  |  | 4.99% |  |  |
Minimum | Series B Convertible Preferred Stock |  |  |  |  |  |  |  |  |  |
Class Of Stock [Line Items] |  |  |  |  |  |  |  |  |  |
Percentage of common stock to be held for conversion |  |  |  |  |  |  | 4.99% |  |  |

X
- Definition Class of warrant or right issued. + References No definition available. + Details
Name: | dvax_ClassOfWarrantOrRightIssued
Namespace Prefix: | dvax_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Combined price of common stock and warrant. + References No definition available. + Details
Name: | dvax_CombinedPriceOfCommonStockAndWarrant
Namespace Prefix: | dvax_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Combined price of preferred stock and warrant. + References No definition available. + Details
Name: | dvax_CombinedPriceOfPreferredStockAndWarrant
Namespace Prefix: | dvax_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Common stock sales agreement aggregate sales proceeds. + References No definition available. + Details
Name: | dvax_CommonStockSalesAgreementAggregateSalesProceeds
Namespace Prefix: | dvax_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of common stock preferred stock convertible into. + References No definition available. + Details
Name: | dvax_NumberOfCommonStockPreferredStockConvertibleInto
Namespace Prefix: | dvax_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of common stock held not to exceed by holder and affiliates for warrant exercises. + References No definition available. + Details
Name: | dvax_PercentageOfCommonStockHeldNotToExceedByHolderAndAffiliatesForWarrantExercises
Namespace Prefix: | dvax_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of common stock to be held by holder and affiliates for conversion of preferred stock. + References No definition available. + Details
Name: | dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForConversionOfPreferredStock
Namespace Prefix: | dvax_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of common stock to be held by holder and affiliates for exercise of warrants. + References No definition available. + Details
Name: | dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForExerciseOfWarrants
Namespace Prefix: | dvax_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Preferred stock deemed dividend. + References No definition available. + Details
Name: | dvax_PreferredStockDeemedDividend
Namespace Prefix: | dvax_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Price of common stock. + References No definition available. + Details
Name: | dvax_PriceOfCommonStock
Namespace Prefix: | dvax_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Proceeds from issuance of common stock authorized, remaining capacity. + References No definition available. + Details
Name: | dvax_ProceedsFromIssuanceOfCommonStockAuthorizedRemainingCapacity
Namespace Prefix: | dvax_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition proceeds from warrants sale. + References No definition available. + Details
Name: | dvax_ProceedsFromWarrantsSale
Namespace Prefix: | dvax_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Selling commission percentage from gross offering proceeds of sales of stock. + References No definition available. + Details
Name: | dvax_SellingCommissionPercentageFromGrossOfferingProceedsOfSalesOfStock
Namespace Prefix: | dvax_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ClassOfStockLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. + References No definition available. + Details
Name: | us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644 + Details
Name: | us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Face amount or stated value per share of common stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_CommonStockSharesOutstanding
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 860 -SubTopic 20 -Section 50 -Paragraph 4D -Subparagraph (c)(2) -URI http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4B -Subparagraph (a),(c) -URI http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 50 -Paragraph 3 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 55 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313 + Details
Name: | us-gaap_DerivativeFairValueOfDerivativeLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Section 25 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875 + Details
Name: | us-gaap_FairValueAdjustmentOfWarrants
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash outflow for cost incurred directly with the issuance of an equity security. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585 + Details
Name: | us-gaap_PaymentsOfStockIssuanceCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_PreferredStockParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_PreferredStockSharesOutstanding
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash inflow from the additional capital contribution to the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromIssuanceOrSaleOfEquity
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=dvax_BainLifeSciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=dvax_BainCapitalLifeSciencesFundLimitedPartnerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=dvax_BCIPLifeSciencesAssociatesLimitedPartnersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=dvax_TwentySeventeenAtTheMarketAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=dvax_SeriesBConvertiblePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |